157 results
Page 3 of 8
8-K
EX-1.1
h50za
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
424B5
d7ih7xdx7xjpriyj9q
12 Dec 22
Prospectus supplement for primary offering
6:03am
424B5
63veggjy95jfrs3m7l
7 Dec 22
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
65weq16d
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
8-K
EX-99.2
hmjd3qbpn3p1bcesr7
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
8-K
EX-99.1
8yldfjf okf
3 Nov 22
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
8:11am
8-K
EX-99.1
b7pvbda7k 1j7spu26
7 Oct 22
Entry into a Material Definitive Agreement
8:20am
8-K
EX-99.1
g7r03la2r5 otbct
4 Aug 22
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
8:10am
8-K
EX-99.1
wx8jr6z6p5kp
3 Jun 22
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
8:10am
8-K
EX-99.1
f3f8gafbq8ot fg08
19 May 22
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
8:10am
8-K
EX-99.1
wrha7n
30 Mar 22
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
7:28am
8-K
EX-99.1
5h6gdt8xxlg07
3 Feb 22
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
8:16am